Research programme: poly-receptor opioid-like pain and drug addiction therapeutics - Phoenix PharmaLabs

Drug Profile

Research programme: poly-receptor opioid-like pain and drug addiction therapeutics - Phoenix PharmaLabs

Alternative Names: Opioid derivatives - Phoenix PharmaLabs; PPL 103

Latest Information Update: 23 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Phoenix PharmaLabs
  • Developer Aoxing Pharmaceutical Company; Phoenix PharmaLabs
  • Class Opioid analgesics
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Drug abuse; Pain

Most Recent Events

  • 15 Oct 2018 Phoenix PharmaLabs plans a phase I trial of PPL 103
  • 25 Sep 2018 Preclinical development is ongoing in Pain and Drug abuse in USA and China
  • 25 Sep 2018 Phoenix PharmaLabs intends to file an IND with US FDA for clinical development in Pain and Drug abuse by March 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top